Next 10 |
TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna ") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“ Ceapro ”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approvin...
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 - All-stock merger of equals transaction with Ceapro, Inc. expected to close i...
TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“ Ceapro ”) are pleased to announce that securityholders of both biopharmaceutical devel...
ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts appear to have been reasonably managed.” ISS states in it...
Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value proposition More information and materials available at www.AEZSmerger.com Shareholders with questions or who ...
2024-02-15 17:33:01 ET More on Aeterna Zentaris Aeterna Zentaris and Ceapro to merge in all-stock deal Seeking Alpha’s Quant Rating on Aeterna Zentaris Historical earnings data for Aeterna Zentaris Financial information for Aeterna Zentaris R...
2023-12-14 08:15:55 ET More on Aeterna Zentaris, Ceapro, etc. Seeking Alpha’s Quant Rating on Aeterna Zentaris Historical earnings data for Aeterna Zentaris Financial information for Aeterna Zentaris Financial information for Ceapro For further...
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“ Ceapro ”), two innovative biopharmaceutical development companies, today announced that they h...
2023-11-09 08:56:55 ET More on Aeterna Zentaris Seeking Alpha’s Quant Rating on Aeterna Zentaris Historical earnings data for Aeterna Zentaris Financial information for Aeterna Zentaris For further details see: Aeterna Zentaris GAAP EPS of -$0.85
- Launch of Ghryvelin ™ in a number of key countries in the European Economic Area - Approval of Macrilen ® in South Korea in September - Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority pipeline prog...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna") and Ceapro ...
TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna ") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“ Ceapro ”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approvin...
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 - All-stock merger of equals transaction with Ceapro, Inc. expected to close i...